mesothelioma: your questions and future treatment options susie harden 1/4/11
TRANSCRIPT
![Page 1: Mesothelioma: your questions and future treatment options Susie Harden 1/4/11](https://reader030.vdocument.in/reader030/viewer/2022032703/56649d095503460f949dbd22/html5/thumbnails/1.jpg)
Mesothelioma: your questions and future treatment options
Susie Harden 1/4/11Susie Harden 1/4/11
![Page 2: Mesothelioma: your questions and future treatment options Susie Harden 1/4/11](https://reader030.vdocument.in/reader030/viewer/2022032703/56649d095503460f949dbd22/html5/thumbnails/2.jpg)
Future possibilities in Cambridge
First line studiesFirst line studies Second line studiesSecond line studies Phase 1 studiesPhase 1 studies Biobank: potential for individually tailored Biobank: potential for individually tailored
treatments in the future?treatments in the future?
![Page 3: Mesothelioma: your questions and future treatment options Susie Harden 1/4/11](https://reader030.vdocument.in/reader030/viewer/2022032703/56649d095503460f949dbd22/html5/thumbnails/3.jpg)
First line studies coming soon
MESO 2: phase II study of adding MESO 2: phase II study of adding vorinostat to pemetrexed /cisplatin vorinostat to pemetrexed /cisplatin [this agent is a histone deacetylase inhibitor and acts to [this agent is a histone deacetylase inhibitor and acts to ‘unblock’ certain genes in tumour cells ‘unblock’ certain genes in tumour cells
ADAM: Phase II study of pegylated ADAM: Phase II study of pegylated arginine deaminase/placebo arginine deaminase/placebo [when chemotherapy not indicated in ASS (arginosuccinate [when chemotherapy not indicated in ASS (arginosuccinate synthetase) negative patients. (this agent depletes tumours synthetase) negative patients. (this agent depletes tumours of an essential amino acid – arginine)]of an essential amino acid – arginine)]
![Page 4: Mesothelioma: your questions and future treatment options Susie Harden 1/4/11](https://reader030.vdocument.in/reader030/viewer/2022032703/56649d095503460f949dbd22/html5/thumbnails/4.jpg)
Secondline studies
No standard treatment but re-challenge with No standard treatment but re-challenge with pemetrexed if good first time response pemetrexed if good first time response acceptedaccepted
No imminent trials in CambridgeNo imminent trials in Cambridge
![Page 5: Mesothelioma: your questions and future treatment options Susie Harden 1/4/11](https://reader030.vdocument.in/reader030/viewer/2022032703/56649d095503460f949dbd22/html5/thumbnails/5.jpg)
Phase 1 studies in Cambridge
S222611 SHINOGIS222611 SHINOGI[a dual EGFR and HER2 small molecule inhibitor][a dual EGFR and HER2 small molecule inhibitor]
Radiotherapy (your feedback please!)Radiotherapy (your feedback please!)
Tomotherapy dose-wash diagram
![Page 6: Mesothelioma: your questions and future treatment options Susie Harden 1/4/11](https://reader030.vdocument.in/reader030/viewer/2022032703/56649d095503460f949dbd22/html5/thumbnails/6.jpg)
Over to you!
Any questions?Any questions?
Any suggestions?Any suggestions?